The open-label, dose-escalating Phase I/II trial is designed to evaluate the safety and preliminary efficacy of sub-retinal administration of SPK-CHM. Spark co-founder and chief executive officer Jeffrey Marrazzo
The ten-year indefinite delivery/indefinite quantity contract will see DVC and its teaming partners, Quintiles, Health Decisions and WCCT Global, supporting and conducting Phase I clinical trials of infectious
Phoxillum, a pre-mixed solution containing phosphate in a 5l bag, is designed to treat hypophosphatemia in patients receiving CRRT, such as in an intensive care environment for patients
Deflazacort is a glucocorticoid with anti-inflammatory and immunosuppressant properties. Currently, there are no approved therapies for DMD in the US, where it affects around 20,000 people. The company
Administered as a once-daily single injection independently of meals, Xultophy is a combination of basal insulin Tresiba (insulin degludec) and GLP-1 analogue Victoza (liraglutide). The product is intended
The injection is indicated for reversal of the effects of nondepolarizing neuromuscular blocking agents (NMBA) after surgery. The drug is claimed to be the first approved by the
If approved, paliperidone palmitate will be the first and only long-acting atypical antipsychotic that has a dosing schedule of just four times a year. Schizophrenia is a complex
The approval follows an expedited review and positive opinion issued by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) in November 2014. In
In order to further develop several series of Orexin-1 selective inhibitors, Evotec will apply its drug discovery platform with C4XD. Activation of the orexin-1 receptor in the brain
Cosentyx 300mg is the first and only interleukin-17A (IL-17A) inhibitor to be approved in Europe providing a new first-line biologic treatment option for these patients. At present, all
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.